Syntis Bio develops oral therapies that utilize SYNT SYNthetic Tissue-lining technology to create a transient polymer coating in the duodenum, optimizing nutrient uptake and enhancing drug absorption for metabolic control. Their lead product, SYNT-101, is a once-daily oral pill designed to treat obesity by mimicking the effects of gastric bypass surgery.
Funding
$15.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity is a widespread health concern with limited effective and accessible treatment options beyond invasive surgical procedures. Current pharmaceutical interventions often have significant side effects or limited efficacy, leaving a substantial unmet need for safe and convenient therapies that can promote weight loss and improve metabolic health.
Solution
Syntis Bio is developing oral therapies based on its proprietary SYNT Synthetic Tissue-lining technology, which creates a temporary polymer coating in the duodenum to optimize nutrient uptake and enhance drug absorption. Their lead product, SYNT-101, is a once-daily oral pill designed to treat obesity by mimicking the effects of gastric bypass surgery without the need for surgical intervention. This approach aims to provide a more accessible, effective, and sustainable therapeutic solution for managing obesity and related metabolic disorders.
Target Audience
The primary target audience includes individuals with obesity and related metabolic disorders seeking a non-surgical, orally administered therapeutic option for weight management and improved metabolic health.
Features
- SYNT Synthetic Tissue-lining technology for transient polymer coating of the duodenum
- Once-daily oral pill formulation for convenient administration
- Mimics the effects of gastric bypass surgery without surgical intervention
- Designed to optimize nutrient uptake and enhance drug absorption
- Potential application for treating obesity, diabetes, and rare diseases